SCHEMBL6489657

SCHEMBL6489657

Cc1cc(COc2cc(C(=O)O)ccn2)cc2c1nc(C)n2Cc1ccc(Cl)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 7/20 0.42
KDM5A P29375 6/20 0.42
KDM5B Q9UGL1 6/20 0.42
KDM2B Q8NHM5 4/20 0.42
KDM4A O75164 2/20 0.42
KDM4E B2RXH2 1/20 0.42
KDM6B O15054 1/20 0.42
KDM4B O94953 1/20 0.42
KDM4D Q6B0I6 1/20 0.42
KDM2A Q9Y2K7 1/20 0.42
KDM3A Q9Y4C1 1/20 0.42
DCTPP1 Q9H773 1/20 0.40
P2RX3 P56373 2/20 0.39
MRGPRX4 Q96LA9 3/20 0.39
PPARG P37231 1/20 0.39
NR4A2 P43354 2/20 0.38
NR4A1 P22736 1/20 0.38
NR4A3 Q92570 1/20 0.38
ALOX5AP P20292 1/20 0.37
SLC16A3 O15427 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490180 0.91 LMNA (0.41) KDM4CKDM4EDCTPP1P2RX3PPARG
SCHEMBL6490213 0.90 MRGPRX4 (0.40) KDM4CKDM5AKDM5BKDM2BKDM4A
SCHEMBL6501562 0.86 NR4A2 (0.57) MRGPRX4PPARGNR4A2NR4A1NR4A3
SCHEMBL6498704 0.84 P2RX3 (0.45) P2RX3MRGPRX4PPARG
SCHEMBL6494714 0.82 KDM4C (0.44) KDM4CKDM5AKDM5BKDM2BKDM4A
SCHEMBL6495987 0.82 PIK3C2B (0.41) P2RX3MRGPRX4PPARGALOX5APSLC16A3
SCHEMBL6491685 0.82 FABP3 (0.46) MRGPRX4ALOX5AP
SCHEMBL6172911 0.81 PPARG (0.48) DCTPP1MRGPRX4PPARGNR4A2
SCHEMBL7200058 0.81 FABP3 (0.48) MRGPRX4ALOX5AP
SCHEMBL6488333 0.80 MRGPRX4 (0.43) KDM4CKDM5ADCTPP1MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD KDM4C 443/4885KDM5A 682/4885KDM5B 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.